moneyheap
CERT · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Certara, Inc. Common Stock (CERT) stock moving?
Certara's Q3 2026 results on Nov 5 showed software revenue up 11% to $48.8M, its first double-digit quarter in two years, while services fell 2% to $46.1M. Total revenue of $94.9M beat the $92.9M estimate, adjusted EBITDA rose 6% to $30.2M with the margin up more than 370 basis points from Q2, and the net loss narrowed to $3.6M. The company ended the quarter with $214.9M in cash. Against that, management narrowed 2026 revenue growth to 2% to 3% and set adjusted EPS guidance at $0.31-$0.34, with the top end below the $0.34 consensus. The interim CFO role and the new Chief Product Officer appointment are also noted in the filings. The stock rose from $11.09 on Nov 4 to $12.18 on Nov 5 (+9.8%) on 3.7M shares, then traded up to $12.60 on Nov 9 on the heaviest volume in the window (5.8M shares). It closed at $12.125 on Nov 10 on lower volume (2.9M), so momentum has cooled. The stock is up about 20% from $10.09 on Oct 22. Analyst reaction is mixed: UBS downgraded to Neutral with a $13 target on Nov 6, while Barclays kept Equal-Weight and raised its target to $12, close to the current price. Near-term, the $11 area (the Nov 4 close) and the $12.60 high frame the recent range.
News behind the analysis
- Certara Reports Third Quarter 2026 Financial ResultsRevenue rose 4% to $94.9M, with software revenue up 11% to $48.8M and adjusted EBITDA of $30.2M at a 31.8% margin. The company also narrowed its 2026 revenue growth outlook to 2% to 3%.
- Certara Narrows FY2026 Adj EPS Guidance from $0.31-$0.36 to $0.31-$0.34 vs $0.34 Est; Revenue for 2026 FY is expected to be up by 2% to 3% YoYAdjusted EPS guidance was narrowed to $0.31-$0.34, with the top end below the $0.34 consensus estimate. Revenue growth guidance is 2% to 3% year over year.
- Certara Q3 Adj. EPS $0.09, Inline, Sales $94.901M Beat $92.867M EstimateAdjusted EPS of $0.09 was in line with expectations, while revenue of $94.9M beat the $92.9M estimate.
- Certara Q3 2026 Earnings Call TranscriptManagement transcript of the third-quarter 2026 earnings call, covering software momentum and operating actions taken in the first half.
- UBS Downgrades Certara to NeutralUBS cut its rating on Certara from Buy to Neutral and set a $13 price target.
- Barclays Maintains Equal-Weight on Certara, Raises Price Target to $12Barclays kept an Equal-Weight rating on Certara and raised its price target to $12, close to the recent trading level.
About Certara, Inc. Common Stock
Certara, based in Radnor, Pennsylvania, sells biosimulation software and consulting that help drug makers use computer models to predict how drugs will behave in the body, so they can design trials and support regulatory filings. It is a leader in model-informed drug development (MIDD). Its customers include more than 2,600 biopharma companies, academic groups and regulators, and in 2026 it sold its regulatory and medical writing unit to focus on MIDD and AI-enabled tools.
How it makes money
Revenue is split roughly in half between two sources. Software brings in about 51% through licenses and subscriptions for tools such as Simcyp and Phoenix, plus clinical-data products like Pinnacle 21. Services bring in about 49% from biosimulation and consulting work for drug developers. In Q3 2026, continuing operations had about $95M in revenue: software grew about 11% and services fell about 2%.
What usually moves CERT
- Biotech and pharma R&D spending and biotech funding
- Software revenue growth versus weak services demand
- Regulatory acceptance of modeling, such as FDA moves to reduce animal testing
- Updates to full-year guidance and management changes
- Adoption of AI-enabled drug development tools